Detecting and treating breast cancer resistance to EGFR inhibitors
Patent
·
OSTI ID:1245595
The application describes therapeutic compositions and methods for treating cancer. For example, therapeutic compositions and methods related to inhibition of FAM83A (family with sequence similarity 83) are provided. The application also describes methods for diagnosing cancer resistance to EGFR inhibitors. For example, a method of diagnosing cancer resistance to EGFR inhibitors by detecting increased FAM83A levels is described.
- Research Organization:
- Lawrence Berkeley National Laboratory (LBNL), Berkeley, CA (United States)
- Sponsoring Organization:
- USDOE
- DOE Contract Number:
- AC02-05CH11231
- Assignee:
- The Regents of the University of California (Oakland, CA)
- Patent Number(s):
- 9,303,088
- Application Number:
- 13/248,690
- OSTI ID:
- 1245595
- Resource Relation:
- Patent File Date: 2011 Sep 29
- Country of Publication:
- United States
- Language:
- English
A Phase I Study of Chemically Synthesized Verotoxin (Shiga-like Toxin) Pk-Trisaccharide Receptors Attached to Chromosorb for Preventing Hemolytic-Uremic Syndrome
|
journal | April 1995 |
Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer
|
journal | January 2009 |
Epidermal Growth Factor Receptor Gene Expression in Estrogen Receptor-Positive and Negative Human Breast Cancer Cell Lines
|
journal | March 1987 |
Similar Records
Targeting SHP2 for EGFR inhibitor resistant non-small cell lung carcinoma
Mechanism of c-Met and EGFR tyrosine kinase inhibitor resistance through epithelial mesenchymal transition in non-small cell lung cancer
Novel irreversible EGFR tyrosine kinase inhibitor 324674 sensitizes human colon carcinoma HT29 and SW480 cells to apoptosis by blocking the EGFR pathway
Journal Article
·
Fri Oct 04 00:00:00 EDT 2013
· Biochemical and Biophysical Research Communications
·
OSTI ID:1245595
+2 more
Mechanism of c-Met and EGFR tyrosine kinase inhibitor resistance through epithelial mesenchymal transition in non-small cell lung cancer
Journal Article
·
Fri Sep 02 00:00:00 EDT 2016
· Biochemical and Biophysical Research Communications
·
OSTI ID:1245595
+4 more
Novel irreversible EGFR tyrosine kinase inhibitor 324674 sensitizes human colon carcinoma HT29 and SW480 cells to apoptosis by blocking the EGFR pathway
Journal Article
·
Fri Aug 12 00:00:00 EDT 2011
· Biochemical and Biophysical Research Communications
·
OSTI ID:1245595
+2 more